6.4148  -0.085 (-1.31%)		10-24 14:56
Open: 6.35 High: 6.62 Volume: 48,146		Pre. Close: 6.5 Low: 6.35 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	9.74	1-year :	11.37
Resists	First :	8.34	Second :	9.74
Pivot price	6.72
Supports	First :	5.59	Second :	3.9
MAs	MA(5) :	6.69	MA(20) :	6.15
	MA(100) :	6.67	MA(250) :	11.87
MACD	MACD :	0.5	Signal :	0.5
%K %D	K(14,3) :	56.7	D(3) :	60.7
RSI	RSI(14): 56
52-week	High :	39.2	Low :	0.75

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ACXP ] has closed above bottom band by 44.5%. Bollinger Bands are 1.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.63 - 6.68	6.68 - 6.71
Low:	6.28 - 6.32	6.32 - 6.35
Close:	6.44 - 6.51	6.51 - 6.57

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Wed, 08 Oct 2025
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - ts2.tech

Wed, 08 Oct 2025
ACXP’s Steady Climb: New Developments? - timothysykes.com

Wed, 08 Oct 2025
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga

Wed, 08 Oct 2025
Pharma Boom: Acurx on the Rise - StocksToTrade

Mon, 06 Oct 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Corpus Christi Caller-Times

Tue, 30 Sep 2025
20,000 Children Affected Annually: Acurx's New Antibiotic Gets Key EMA Support for C. difficile Treatment - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	8.1 (%)
Held by Institutions	13.8 (%)
Shares Short	64 (K)
Shares Short P.Month	39 (K)

EPS	-10.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.42
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-98.6 %
Return on Equity (ttm)	-286 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.62
PEG Ratio	0
Price to Book value	2.68
Price to Sales	0
Price to Cash Flow	-1.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.